The proposed U19 will consist of four interdigitating projects that are dependent for success on the integrated scientific interaction among project leaders. For this reason, an Administrative Core is proposed to assist Dr. Reinherz in communications between project leaders and members of their groups, both on-site (DFCI) and off-site (Harvard Medical School, MIT, Northeastern and Duke University Medical School) as well as with various consultants. Because of NIAID participation in collection and analysis of data, obligation for broad data sharing and web-based dissemination of information and methodologies, a well-organized administrative component is essential. The core will facilitate all forms of communication with various project components (phone, email, fax, etc.). The budget will include funds for communication costs, clerical and financial work and for an annual B Cell Immunology Partnership Program Meeting travel for project leaders as well as SAB members to be appointed. Oversight for statistical support, web-based data sharing and dissemination of methodologies relevant to various development efforts are incorporated. An Administrative Partnership Plan and budget to cover the costs of developing a communications network and sponsoring an annual B cell workshop for HIV-1 vaccine discovery are included.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI091693-04
Application #
8516454
Study Section
Special Emphasis Panel (ZAI1-PTM-A)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2013
Total Cost
$79,858
Indirect Cost
$12,073
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Verkoczy, Laurent; Kelsoe, Garnett; Haynes, Barton F (2014) HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog 10:e1004073
Hanson, Melissa C; Bershteyn, Anna; Crespo, Monica P et al. (2014) Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding. Biomacromolecules 15:2475-81
Sitkovsky, Michail V; Hatfield, Stephen; Abbott, Robert et al. (2014) Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res 2:598-605
Sun, Zhen-Yu J; Cheng, Yuxing; Kim, Mikyung et al. (2014) Disruption of helix-capping residues 671 and 674 reveals a role in HIV-1 entry for a specialized hinge segment of the membrane proximal external region of gp41. J Mol Biol 426:1095-108
Liu, Haipeng; Moynihan, Kelly D; Zheng, Yiran et al. (2014) Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507:519-22
Holl, T Matt; Yang, Guang; Kuraoka, Masayuki et al. (2014) Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-79
Irvine, Darrell J; Swartz, Melody A; Szeto, Gregory L (2013) Engineering synthetic vaccines using cues from natural immunity. Nat Mater 12:978-90
Kim, Mikyung; Song, Likai; Moon, James et al. (2013) Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. J Biol Chem 288:31888-901
Cain, Derek W; Sanders, Sergio E; Cunningham, Michael M et al. (2013) Disparate adjuvant properties among three formulations of "alum". Vaccine 31:653-60
Moon, James J; Suh, Heikyung; Li, Adrienne V et al. (2012) Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 109:1080-5

Showing the most recent 10 out of 12 publications